NASDAQ:NEUP Neuphoria Therapeutics Q4 2026 Earnings Results & Report $3.04 -0.01 (-0.33%) Closing price 11/2/2026 04:00 PM EasternExtended Trading$3.04 0.00 (0.00%) As of 11/2/2026 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Neuphoria Therapeutics was expected to report Q4 2026 earnings on October 5, 2026, before market opens. Analysts expected earnings of -$1.58 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Announcement DateOctober 5, 2026TimeBefore Market Opens Neuphoria Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.58Beat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 6 quartersNeuphoria Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Neuphoria Therapeutics Earnings HeadlinesNeuphoria Therapeutics Inc. enters into Amendment No. 1 to rights agreement to extend expiration date to October 27, 2027October 23, 2026 | msn.comNeuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 19, 2026 | marketscreener.comMBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | Decentralized Masters (Ad)Neuphoria Therapeutics Inc Ordinary Shares NEUPAugust 14, 2026 | morningstar.comMNeuphoria Therapeutics Inc (NEUP)August 8, 2026 | investing.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.comSee More Neuphoria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email. Email Address About Neuphoria TherapeuticsNeuphoria Therapeutics (NASDAQ:NEUP) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. Its work is directed toward addressing significant unmet medical needs in central nervous system medicine. The company is advancing an investigational pipeline of therapeutic candidates and is primarily engaged in pharmaceutical research and development. Publicly available information does not provide sufficient detail to reliably identify specific marketed products, served geographies, or the company’s current leadership. As a development-stage biotechnology company, Neuphoria Therapeutics’ progress is dependent on research results, clinical development, regulatory review, and the potential commercialization of successful therapies.View Neuphoria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
